Vanda Pharmaceuticals’ BLA for imsidolimab in GPP accepted by FDA (target action Dec 2026). Phase 3 GEMINI-1 and GEMINI-2 showed 53% skin clearance at Week 4 vs 13% placebo, with sustained efficacy and favorable safety. Precision IL-36 inhibitor addresses unmet need in rare, life-threatening autoinflammatory disorder.
Written By: Nikita Chaudhari BPharm
Reviewed By: Pharmacally Editorial Team
Vanda Pharmaceuticals Inc. has reached a pivotal milestone with the U.S. Food and Drug Administration (FDA) accepting its Biologics License Application (BLA) for imsidolimab, a targeted monoclonal antibody for generalized pustular psoriasis (GPP).
The FDA has set a target action date of December 12, 2026, signaling potential approval for this rare, life-threatening skin disorder.
Imsidolimab, a fully humanized IgG4 monoclonal antibody licensed exclusively from AnaptysBio, directly blocks IL-36 receptor signaling to restore balance. This precision approach addresses the molecular root cause, differentiating it from broader immunosuppressants.
Global trials spanned the U.S., Europe, Asia, and North Africa, including pivotal Phase 3 studies GEMINI-1 (NCT05352893) and GEMINI-2 (NCT05366855).
In these trials, a single intravenous dose delivered striking results 53% of patients achieved clear or almost clear skin (GPPPGA score 0/1) by Week 4, versus just 13% on placebo. Maintenance with monthly doses sustained efficacy over about two years, with zero flares in the treatment arm.
The drug also proved safe, with few anti-drug antibodies a common issue that can limit other biologics’ effectiveness.
Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO, and Chairman, emphasized the breakthrough: “Imsidolimab builds on our growing expertise in rare orphan disorders and our anti-inflammatory portfolio. It represents precision medicine for a genetically driven condition.”
GPP stands out as a chronic autoinflammatory condition marked by sudden, widespread pustules, red inflamed skin (erythema), and severe systemic symptoms like fever and fatigue. Unlike common psoriasis, GPP can be fatal without prompt intervention. Its roots lie in genetic disruptions, particularly variants in the IL36RN gene (OMIM #614204), which encodes the IL-36 receptor antagonist (IL-36Ra).
This leads to unchecked activity in the interleukin-36 (IL-36) signaling pathway, driving inflammation. Prevalence varies regionally estimated at 2–124 cases per million globally, rarer in Europe and higher in Asia making GPP a classic orphan disease with few targeted options.
The BLA acceptance coincides with Rare Disease Week on Capitol Hill (February 24–26, 2026), underscoring advocacy for therapies like this.
If approved, imsidolimab would mark Vanda’s third new drug in 12 months, after NEREUS™ (tradipitant) and BYSANTI™ (milsaperidone). With regulatory and patent exclusivity into the late 2030s, it promises lasting impact for GPP patients, filling a critical gap where flares can hospitalize or endanger lives.
Reference
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis, 25 February 2026, Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects with GPP (GEMINI1), ClinicalTrials.gov ID NCT05352893, https://clinicaltrials.gov/study/NCT05352893
Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects with Generalized Pustular Psoriasis (GEMINI-2), ClinicalTrials.gov ID NCT05366855, https://clinicaltrials.gov/study/NCT05366855
About Writer
Nikita Chaudhari, B.Pharm
She is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, particularly inclined towards publication writing and scientific content development. In her words, she is enthusiastic about scientific documentation and publication writing, aiming to contribute to accurate, ethical, and evidence-based medical communication.